Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck KGaA

Showing 15 posts of 91 posts found.

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023
Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …

News
mr058666-web

Merck KGaA’s cancer drug Bavencio gets EU approval

January 25, 2021
Sales and Marketing Merck KGaA

The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally …

News
bel-n-garijo-large

Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO

September 30, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA

German pharma firm Merck KGaA has taken the decision to appoint its first female Chief Executive Officer in its 352-year …

News
shutterstock_159488225

Bavencio Phase 3 head and neck cancer trial terminated

March 16, 2020
Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …

News
shutterstock_512649

Merck KGaA to flog Allergopharma business to Dermapharm

February 21, 2020
Medical Communications, Sales and Marketing Allergopharma, Dermapharm, Merck KGaA, pharma

German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of …

News
lynn_taylor_updated_headshot_web

Realising the potential of greater collaboration for women living with cancer

January 27, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Merck KGaA, feature, pharma, women

Following the launch of a new global report, ‘Supporting women with cancer’, Lynn Talyroe, Senior Vice President, Head of Healthcare …

Feature
shutterstock_38078521

Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma

January 7, 2020
Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …

News
diabetes-777001_960_720

New report reveals shocking knowledge gaps around type 2 diabetes risk factors

November 14, 2019
Medical Communications, Research and Development Merck KGaA, diabetes, pharma, type 2 diabetes

A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type …

News
bavencio

Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

November 8, 2019
Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …

News
credit_-_daniel_leal-olivas-afp

Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer

October 29, 2019
Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …

News
blockchain-3750157_640

Insider Interview: A roadblock for counterfeit drugs?

July 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA, blockchain, fake drugs, feature, pharma

Dr Thomas Endress, Founder, and Dr Frederic Berkermann, co-?Founder, of a new technology being developed at the Merck Innovation Center …

Feature

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019
Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …

News

Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial

March 20, 2019
Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer

Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …

News
mr058666-web

Merck KGaA enters drug discovery partnership with AI firm Itkos

March 15, 2019
Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma

Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …

News
shutterstock_38078521

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

February 18, 2019
Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023